PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale BREAST Cancers, PERCEIVE-BREAST

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

496 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-07-10

Study Completion Date

2026-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a retrospective and prospective study aimed to develop and validate the performance of multi-omics assays for early detection of female breast cancer. The study will enroll approximately 496 participants including participants with breast cancers and participants with breast benign diseases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol

NCT02078570

Breast Cancer

UNKNOWN

Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification

NCT01839045

Breast Cancer

UNKNOWN

Circulating Tumour Cells Characterization in Breast Cancer Patients

NCT06048835

Breast Cancer

RECRUITING

Study of Tumor and Blood Samples From Women With Breast Cancer

NCT00897728

Breast Cancer

UNKNOWN

Blood Levels of Tumor Cells in Predicting Response in Patients Receiving First-Line Chemotherapy for Stage IV Breast Cancer

NCT00898014

Breast Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cancer arm

Baseline blood samples will be collected from participants with new diagnosis breast cancer.

Blood test

Intervention Type DEVICE

Blood test

Benign disease arm

Baseline blood samples will be collected from participants with new diagnosis breast benign disease.

Blood test

Intervention Type DEVICE

Blood test

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood test

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to provide a written informed consent.
* Female, at least 18 years old.

* Pathologically confirmed breast cancer diagnosis or highly suspicious for breast cancer within 42 days prior to blood draw.
* No prior cancer treatment before the blood draw.

* Pathologically confirmed breast cancer diagnosis or highly suspicious of breast benign diseases within 90 days prior to blood draw.
* No prior radical treatment before the blood draw.

Exclusion Criteria

* During pregnancy or lactation.
* Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.
* Recipient of blood transfusion within 7 days prior to blood draw.
* Recipient of anti-tumor drugs to treat non-cancer diseases prior to blood draw, such as rheumatic drugs (methotrexate, cyclophosphamide, or azathioprine), or endocrine drugs (tamoxifen).

* Multiple primary tumors.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No